Treatment Options Post Exposure to COVID-19
Introductory content goes here…
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris placerat ullamcorper sem eu sodales. Praesent suscipit mauris nec augue bibendum, ut consequat massa sodales. Proin et lacus enim. Vivamus vulputate luctus ultrices. Quisque consequat porttitor fringilla. Mauris vitae nulla porttitor, gravida diam et, egestas mauris. Mauris convallis metus at urna rutrum, eget hendrerit metus porttitor. Maecenas posuere lorem rhoncus nisi eleifend mollis.
Web Tip: This has the potential to change everything and give us freedom like that already enjoyed by those vaccinated who have a normal immune system.
CLL Society’s COVID-19 Update for the Week of November 7th, 2022
CLL Society’s COVID-19 Update for the Week of November 7th, 2022: Here is your weekly summary of what has been happening this past week in the United States. The variant picture continues to shift rapidly. Read more on this below.
The CDC Joins the NIH and FDA in Including Chronic Lymphocytic Leukemia Patients, Regardless of Treatment Status, as Being Among the Immunocompromised
First, the National Institutes of Health (NIH), then the Food and Drug Administration (FDA), and most recently, the Center for Disease Control (CDC) are now recognizing that patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) are immunocompromised even when not in treatment.
CLL and COVID-19: Light at the End of the Tunnel?
Dr. Koffman interviewed the lead researcher, Dr. Carsten Niemann, Associate Professor of Hematology at the University of Copenhagen. Dr. Niemann shared encouraging news and a brighter outlook for those of us with CLL in this interview I hope you will enjoy.
ASH 2021: Dr. Jake Soumerai on the Immune Response to COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukemia (CLL)
At the American Society of Hematology (ASH) 2021, our own Dr. Brian Koffman interviewed Dr. Jake Soumerai, a clinical investigator at Massachusetts General Hospital and an Assistant Professor at Harvard Medical School. They discussed some new research that looked at the immune response to COVID-19 vaccination in patients with CLL more comprehensively than just antibody levels.
Dr. Michael Joyner on Convalescent Plasma for Treating COVID-19 in Immunocompromised Patients, including Those with Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
In this interview, our own Dr. Brian Koffman spoke with Dr. Michael Joyner, an anesthesiologist at the Mayo Clinic in Rochester, MN. They discussed the use of convalescent plasma to treat COVID-19.
Update to the FDA Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld
On October 3, 2022, the FDA updated the guidance offered to healthcare providers concerning Evusheld (the cocktail of two COVID-19 monoclonal antibodies, tixagevimab, and cilgavimab). Evusheld which is currently the only authorized Pre-Exposure Prophylaxis (PrEP) against COVID-19 for the immunocompromised, including those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), in whom protection provided by the COVID-19 vaccine is unpredictable and less robust.
RECENT NEWS
When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.
